Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

21 November 2022: Clinical Research

Long-Term Effect of Pancreaticoduodenectomy Combined with Revascularization for Resectable Pancreatic Carcinoma in Elderly Patients

Jiali Yang 1ABCDEF* , Zhengrong Xu 2ABCD* , Junfeng Zhang 1CD , Yao Zheng 1CD , Jianyou Gu 1AC , Qiang Zhou 1CD , Xianxing Wang 1CD , Shixiang Guo 1DF , Hongyu Zhang 3AD , Shengkai Chen 1ADG* , Huaizhi Wang 1ADG*

DOI: 10.12659/MSM.938443

Med Sci Monit 2022; 28:e938443

Table 4 Analysis of the OS and PFS of PDAC patients who underwent PDR according to age.

VariablesOS
Age <60 y (n=97)60 y ≤ Age <70 y (n=51)Age ≥70 y (n=22)P value
Preoperative CA19-9 ≥200 IU/L9.2 (7.638–10.762)7.1 (3.892–10.308)8.1 (3.587–12.613)0.474
Vascular invasion site
 PV14.7 (0.000–33.238)17.9 (6.858–28.942)0.436
 Confluence of PV-SMV7.2 (5.343–9.057)8.9 (6.401–11.399)7.0 (4.690–9.310)0.673
 SMV11.5 (8.386–14.614)8.4 (5.619–11.181)9.1 (4.941–13.259)0.049
Venous reconstruction
 Interposition graft9.7 (8.771–10.629)7.1 (5.566–8.634)6.1 (0.220–11.980)0.628
 End-to-end anastomosis9.6 (7.717–11.283)9.2 (7.048–11.352)8.3 (6.469–10.131)0.693
 Primary closure14.7 (0.000–40.063)0.293
T stage 1/211.2 (8.595–13.805)8.9 (7.783–9.927)9.1 (5.253–12.947)0.509
N stage 1/29.2 (5.764–12.636)8.4 (6.051–10.749)5.9 (0.000–12.968)0.833
TNM stage
 I/II9.7 (7.718–11.682)8.9 (7.845–9.955)10.8 (7.267–14.333)0.736
 III/IV7.1 (1.329–12.871)6.7 (3.580–9.820)3.0 (0.439–5.561)0.479
Degree of differentiation
 Well12.1 (8.278–15.922)6.1 (5.620–6.580)10.9 (0.000–34.329)0.345
 Moderate9.9 (8.036–11.735)10.1 (8.395–11.805)8.3 (6.750–9.850)0.451
 Poor5.8 (5.143–6.457)6.9 (5.256–8.544)4.3 (0.000–11.982)0.977
Postoperative adjuvant antineoplastic therapy14.7 (9.175–20.225)9.2 (5.973–12.427)13.1 (8.591–17.609)0.184
(≥ (
Preoperative CA19-9 ≥200 IU/L6.3 (4.389–8.211)5.0 (2.805–7.195)6.5 (0.000–13.679)0.957
Vascular invasion site
 PV7.1 (2.353–11.847)17.9 (6.858–28.942)0.095
 Confluence of PV-SMV5.0 (3.793–6.207)6.0 (4.736–7.264)5.7 (3.904–7.496)0.998
 SMV7.6 (6.362–8.838)6.2 (1.586–10.814)8.4 (4.395–9.057)0.226
Venous reconstruction
 Interposition graft5.9 (2.491–9.309)4.6 (3.723–5.477)5.7 (0.000–11.580)0.397
 End-to-end anastomosis6.9 (6.444–7.356)7.8 (4.997–10.603)8.3 (4.870–11.730)0.740
 Primary closure12.4 (0.000–34.020)0.303
T stage 1/27.8 (6.549–9.051)6.1 (3.303–8.897)8.4 (4.747–12.053)0.854
N stage 1/25.3 (3.287–7.313)5.8 (3.804–7.796)3.0 (0.000–8.544)0.879
TNM stage
 I/II7.0 (5.808–8.192)6.0 (4.671–7.329)9.1 (5.744–12.456)0.472
 III/IV4.0 (0.945–7.055)6.7 (2.021–11.379)3.0 (0.439–5.561)0.711
Degree of differentiation
 Well6.7 (0.624–12.776)6.1 (5.620–6.580)10.9 (0.000–36.345)0.416
 Moderate7.0 (5.622–8.378)8.2 (5.818–10.582)8.3 (4.271–12.329)0.918
 Poor5.0 (3.028–6.972)4.0 (2.708–5.292)4.3 (0.000–9.485)0.225
Postoperative adjuvant antineoplastic therapy7.9 (6.230–9.570)6.0 (3.849–8.151)11.0 (6.921–15.079)0.281
Postoperative adjuvant therapy includes chemotherapy, radiotherapy, biological therapy, traditional Chinese medicine therapy, etc.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750